About Guzip

Guzip Biomarkers Corporation is a subsidiary of Phalanx Biotech and was established in 2018. Guzip focuses on the research of epigenetics and continually explores clinical applications in the field of methylation research. Products like MPap/RitaPap aim to assist women in leading their best lives at every stage. We are a research-driven company, offering novel DNA methylation epigenetic gene marker screening services for clinical applications.

Team members

Polly Lin, Ph.D.
Co-Founder &CEO

  • 10+ years Biotech and IP experiences
  • VP, Senhwa Biosciences (6492.TW0); 
  • Market Manager, CDIB BioScience Venture Management;
  • Patent Engineer;
  • Postdoc at Georgetown University.

Hung-Cheng Lai, M.D., Ph.D.
Co-Founder &CMO

  • 20+ years Clinician and RD experiences
  • Professor, Taipei Medical University;
  • Vice Supt. and Chair of Ob/Gyn Dept, Shuang Ho Hospital.

Yu-Shu Liu,  Ph.D.
Project Manager, RD Dept.

  • Postdoctoral Fellowship in China Medical University (CMU)
  • PhD from the Institute of Basic Medical Sciences at CMU
  • 13 SCI publications
  • Joined Guzip as RD project manager in February 2020

Lucas Chen
Project Manager, RD Dept.

  • Master’s degree in microbiology from the National Taiwan University (NTU)
  • Licensed medical technologist, B.S. from China Medical University (CMU)
  • Experienced in regulated laboratory settings with ISO17025, ISO15189 and LDTS
  • Previous experience as lab manager and marketing manager in a liquid biopsy company

Hsin-Hui Huang, Ph.D.
Project Manager, RD Dept.

  • PhD and master’s degree from National Yang Ming Chiao Tung University (NYCU)
  • Trained medical technologist at China Medical University (CMU)
  • 9 SCI publications
  • Previous experience as a postdoctoral researcher at NYCU and research assistant at the division of infectious diseases at Taipei Veterans General Hospital

Kuang-Hung, Hsiao, Ph.D.
Project Manager, RD Dept.

  • 1-year postdoctoral research experience
  • Biomedical Engineering PhD from National Central University (NCU)
  • 2 SCI publications
  • Expert in the development of nanoparticles

Michael Muljadi, Ph.D.
Project Manager

  • Biomedical Engineering PhD from National Tsing Hua University (NTHU)
  • Master’s in biomedical engineering from University of Melbourne
  • 3 SCI publications
  • Previous experience as a junior consultant at McKinsey & Company

Rhema Tang
Rhema consultant

  • Primary Expertise: Corporate Management, Marketing, Channel Structure, Education and Training.
  • With over 15 years of experience in venture capital and the biotechnology industry. Holds an international license as a first-level financial planner.
  • In 2016, signed a collaboration agreement with Genequest, the leading gene testing company in Japan, bringing over 290 comprehensive gene testing services to Taiwan. Services expanded to Hong Kong and Mainland China
  • Played a key role in establishing a service network for gene testing products in the chain of health insurance pharmacies in Taiwan. Additionally, served as a consultant and lecturer for various clinics, pharmacies, and biotech companies.

History

2022 November

  • Won the 2022 Global Biotech Taiwan New Startup CEO Award “2022 – The 10 Best Bio Startup CEOs”
  • Won the 29th Small and Medium Enterprise Innovation Research Award
  • Won the 21st New Entrepreneurship Award-Technology Industry Group Gold Award
  • Won the 2022 National Pharmaceutical Science and Technology Research and Development Award – Silver

2022 January

The company moved to the Hsinchu Biomedical Science Park in line with business development

2021 December

Guzip Biomarkers Corporation was acquired by Phalanx Biotech

2021 July

The MPap® endometrial cancer detection reagent has obtained Level III medical material certification from the Food and Drug Administration of the Ministry of Health and Welfare.

2020 December

Guzip has been awarded the “Ministry of Health and Welfare, Ministry of Economic Affairs Pharmaceutical Technology Research and Development Award – Medical Devices Category” for the “MPap® BHLHE22/CDO1 Gene Methylation Detection Kit.”

2020 November

Guzip has been honored with the 9th Women Entrepreneurship Award – Technology Innovation category.

2020 May

Guzip launches the MPap Service into the Taiwan Market.

2020 January

Guzip moved its office to a new location at Zhonghe Dist., New Taipei City.

2019 December

Guzip has reached an agreement with TSH Biopharm.

2019 November

Guzip participated in RESI Taipei and was awarded the first place for the most promising startup in market development at RESI.

2019 May

Guzip received a subsidy of 1 million NTD from the Ministry of Science and Technology’s “TTA Prototype Technology Innovation and Creativity Program”.

2019 February

Guzip got a subsidy up to NTD$1,000,000 from “Project of Subsidies & Incentives For Taipei Industry”.

2018 December

The co-founder, Hung-Cheng Lai, M.D, of Guzip won Top 5 academia-industry collaboration highlight project in 2018 announced by Ministry Of Science And Technology.

2018 November

Guzip gains global recognition for Top 100 Science Spinoffs in SDB rankings for 2018.

2018 October

Guzip and Taipei Medical University signed an exclusive global patent license agreement for endometrial cancer diagnosis methodology.  Guzip has completed a Seed financing round.

2018 September

Guzip office was relocated to a new address.

2018 August

Guzip begins operations in Taiwan.

Scroll to Top